---
layout: full_article
title: "Pembedahan Kanker di Masa Pandemi COVID-19"
author: "I Wayan Sudarsa"
categories: jbn
canonical_url: https://jurnal.harianregional.com/jbn/full-58983 
citation_abstract_html_url: "https://jurnal.harianregional.com/jbn/id-58983"
citation_pdf_url: "https://jurnal.harianregional.com/jbn/full-58983"  
comments: true
---

<img src="https://jurnal.harianregional.com/media/58983-1.jpg" alt="" style="width:70pt;height:27pt;">
<p><span class="font9">DIRECTORY OF</span></p>
<p><span class="font9">OPEN ACCESS</span></p>
<p><span class="font9">JOURNALS</span></p>
<p><span class="font7">P-ISSN:</span><a href="http://u.lipi.go.id/1481204884"><span class="font7"> 2548-5962</span></a></p>
<p><span class="font7">E-ISSN:</span><a href="http://u.lipi.go.id/1483969293"><span class="font7"> 2548-981X</span></a></p>
<p><a href="https://ojs.unud.ac.id/index.php/jbn"><span class="font7">https://ojs.unud.ac.id/index.php/jbn</span></a></p>
<div>
<p><span class="font3" style="font-weight:bold;">EDITORIAL</span></p>
</div><br clear="all">
<div><img src="https://jurnal.harianregional.com/media/58983-2.jpg" alt="" style="width:103pt;height:65pt;">
</div><br clear="all">
<p><span class="font11" style="font-weight:bold;">Pembedahan Kanker di Masa Pandemi COVID-19</span></p>
<p><span class="font9" style="font-weight:bold;">I Wayan Sudarsa</span></p>
<p><span class="font8">Divisi Bedah Onkologi, Departemen Ilmu Bedah, Fakultas Kedokteran Universitas Udayana, RSUP Sanglah Denpasar.</span></p>
<p><span class="font8">*Penulis korespondensi: </span><a href="mailto:sudarsa1510@yahoo.com"><span class="font8">sudarsa1510@yahoo.com</span></a><span class="font8">.</span></p>
<p><span class="font9" style="font-weight:bold;text-decoration:underline;">DOI: </span><a href="https://doi.org/10.24843/JBN.2020.v04.is01.p01"><span class="font9" style="font-weight:bold;text-decoration:underline;">https://doi.org/10.24843/JBN.2020.v04.is01.p01</span></a></p>
<p><span class="font10" style="font-style:italic;">Corona Virus Disease 2019</span><span class="font10"> (COVID-19), atau yang dikenal juga dengan </span><span class="font10" style="font-style:italic;">Severe Acute Respiratory Syndrome Coronavirus 2 (</span><span class="font10">SARS-CoV-2), ditemukan pertama di Wuhan pada Desember 2019, yang menyebabkan kematian sebesar 12.784 penderita, dan telah menyebar ke beberapa negara.<sup>1</sup> Penyebaran COVID-19 pada tahun 2020 sebesar lebih dari 450.000 kasus di seluruh dunia.<sup>2</sup> Vaksin dan terapi definitif yang memuaskan masih belum tersedia, sehingga </span><span class="font10" style="font-style:italic;">World Health Organization</span><span class="font10"> (WHO) merekomendasikan </span><span class="font10" style="font-style:italic;">social distancing</span><span class="font10"> untuk menekan penyebaran COVID-19.<sup>2</sup> Dampak dari pandemi ini menimbulkan kepanikan bagi seluruh lapisan masyarakat bahkan tenaga medis, karena tidak sedikit tenaga medis yang meninggal dunia akibat tertular COVID-19.<sup>3</sup> Selain itu keterbatasan alat pelindung diri (APD), kapasitas ruang perawatan dan peralatan medis yang terbatas serta jumlah penderita COVID-19 yang semakin meningkat menjadi perhatian khusus bagi tenaga medis.<sup>3</sup></span></p>
<p><span class="font10">Di Wuhan, China, evaluasi pada 34 pasien yang menjalani operasi elektif di empat rumah sakit pada masa inkubasi (1 - 5 Januari 2020) mengalami pneumonia dan terkonfirmasi COVID-19. Didapatkan 15 pasien (44,1%) memerlukan perawatan ICU dengan mortalitas 20,5%.<sup>4</sup></span></p>
<p><span class="font10">Penderita usia tua dan atau dengan komorbid penyakit kronik yang terinfeksi</span></p>
<p><span class="font10">COVID-19 memiliki prognosis yang buruk.<sup>5 </sup>Pada penderita kanker yang terinfeksi oleh COVID-19, maka sangat dibutuhkan peralatan proteksi yang adekuat bagi ahli bedah onkologi dan alat ventilator yang memadai. </span><span class="font10" style="font-style:italic;">American Cancer Society </span><span class="font10">mengumumkan terdapat lebih dari 5.000 kasus kanker yang terinfeksi COVID-19.<sup>5 </sup>Keadaan ini membuat ahli bedah onkologi harus mampu menentukan </span><span class="font10" style="font-style:italic;">“timing”</span><span class="font10"> yang tepat untuk dapat melakukan prosedur diagnostik, terapi bedah secara </span><span class="font10" style="font-style:italic;">“elective” </span><span class="font10">atau tindakan segera </span><span class="font10" style="font-style:italic;">“urgency”</span><span class="font10">, dan </span><span class="font10" style="font-style:italic;">follow up</span><span class="font10"> penderita yang sesuai secara tepat.<sup>5</sup></span></p>
<p><span class="font10">Berdasarkan laporan penelitian di China, penderita kanker dengan COVID-19 memiliki angka morbiditas yang tinggi, termasuk kebutuhan ventilator dengan angka kematian yang tinggi (hazard ratio, 3,56 [95% CI, 1,65 – 7,69].<sup>6</sup> Studi lain di China menunjukkan pasien kanker di pusat epidemik virus memiliki risiko infeksi 2,31 lebih besar [95% CI 1,89 – 3,02] dibandingkan pasien lain.<sup>7</sup></span></p>
<p><span class="font10">Mengingat tingginya angka penyebaran COVID-19 dan tingginya risiko menginfeksi tenaga medis setelah melakukan tindakan pembedahan, kemoterapi atau radiasi, maka seorang ahli bedah onkologi diharapkan dapat menentukan </span><span class="font10" style="font-style:italic;">benefit</span><span class="font10"> dan </span><span class="font10" style="font-style:italic;">risk</span><span class="font10"> dalam penanganan penderita kanker di masa COVID-19, sehingga penting untuk menentukan tindakan </span><span class="font10" style="font-style:italic;">elective</span><span class="font10"> atau </span><span class="font10" style="font-style:italic;">urgency.</span><span class="font10"><sup>8</sup></span></p>
<p><span class="font10">Pada </span><span class="font10" style="font-weight:bold;">Tabel 1 </span><span class="font10">perlu diperhatikan contoh kasus kanker payudara (</span><span class="font10" style="font-style:italic;">early stage</span><span class="font10">) yang memerlukan terapi neoadjuvan adalah kasus yang dapat ditunda sebagai </span><span class="font10" style="font-style:italic;">“delaying surgery”.</span><span class="font10"><sup>8-10</sup> </span><span class="font10" style="font-style:italic;">Society of Surgical Oncology </span><span class="font10">(SSO) merekomendasikan kanker saluran cerna bagian atas (SCBA) cenderung memerlukan tindakan </span><span class="font10" style="font-style:italic;">urgency</span><span class="font10">, terutama yang mengalami obstruktif dan perdarahan aktif.<sup>11 </sup>Sedangkan kanker pada bagian kepala dan leher dapat ditunda selama 4 – 8 minggu selama pandemi COVID-19. Demikian juga</span></p>
<p><span class="font10">pada kanker hepato-pankreato-bilier, apabila terjadi respon setelah pemberian kemoterapi neoadjuvan maka tindakan pembedahan dapat ditunda.<sup>11</sup> Rekomendasi dari </span><span class="font10" style="font-style:italic;">American College of Surgeons</span><span class="font10"> yaitu keputusan untuk melakukan tindakan bedah di masa COVID-19 harus berdasarkan ketersediaan ahli anestesiologi, perawat, dan fasilitas kesehatan yang memadai dalam menghadapi kemungkinan penularan COVID-19, selain itu juga memikirkan komplikasi dan masa perawatan setelah pembedahan.<sup>12</sup></span></p>
<p><span class="font9" style="font-weight:bold;">Tabel 1. </span><span class="font9">Pertimbangan Tindakan Pembedahan Berdasarkan Risiko.</span><span class="font10"><sup>8,9</sup></span></p>
<table border="1">
<tr><td style="vertical-align:top;">
<p><span class="font10">Perti</span></p></td><td style="vertical-align:bottom;">
<p><span class="font10">mbangan Tindakan Bedah pada pasien Kanker dengan</span></p>
<p><span class="font10">COVID-19</span></p>
<p><span class="font5">Low (Aman ditunda &gt;&nbsp;3 bulan)</span></p>
<p><span class="font5">Bedah: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sub>ττ</sub> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;. .</span></p>
<p><span class="font5">..... &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hemato-Zoncologi:</span></p>
<ul style="list-style:none;"><li>
<p><span class="font5">- &nbsp;&nbsp;&nbsp;kanker kulit </span><span class="font5" style="font-style:italic;">nonme Ianoma &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</span></p></li></ul>
<p><span class="font4" style="font-variant:small-caps;">j</span><span class="font5"> ∏ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-Kankerbidanghemotologikronik</span></p>
<ul style="list-style:none;"><li>
<p><span class="font5">- &nbsp;&nbsp;&nbsp;HR+, HER2-, Postmenopausalnon-ZoeiiWy</span></p></li></ul>
<p><span class="font5" style="font-style:italic;">advanced breast cancer</span><span class="font5"> (butuh terapi neoadjuvant &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;_ , , . „ ,. .</span></p>
<p><span class="font5">Onkologi Radiasi: endokrin) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. . , &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,</span></p>
<p><span class="font5"><sub>τ</sub> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- kanker kulit </span><span class="font5" style="font-style:italic;">nonmelanoma</span></p>
<ul style="list-style:none;"><li>
<p><span class="font5">- &nbsp;&nbsp;&nbsp;Low-atau </span><span class="font5" style="font-style:italic;">intermediate</span><span class="font5"> risiko kanker prostat &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;„</span></p></li></ul>
<ul style="list-style:none;"><li>
<p><span class="font5"><sub>1 &nbsp;&nbsp;&nbsp;1 1</sub> &nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- HR+, HER2-, postmenopausal </span><span class="font5" style="font-style:italic;">non-localiy</span></p></li></ul>
<p><span class="font5">-Tipelkankerendometrium &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;,.</span></p>
<ul style="list-style:none;"><li>
<p><span class="font5" style="font-style:italic;">_ &nbsp;&nbsp;&nbsp;,. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sub>j</sub> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sub>1</sub>. . &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;advanced breast cancer</span><span class="font5"> (butuh terapi neoadjuvant</span></p></li>
<li>
<p><span class="font5">- &nbsp;&nbsp;&nbsp;Stadium rendah kanker urotehal &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. , . .</span></p></li></ul>
<p><span class="font5">, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;endokrin)</span></p>
<p><span class="font5">-Kankertiroid &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;_ &nbsp;&nbsp;&nbsp;&nbsp;/ . &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,</span></p>
<p><span class="font5">_ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-Low-UtauznrerffleoKwerisikokankerprostat</span></p>
<ul style="list-style:none;"><li>
<p><span class="font5">- &nbsp;&nbsp;&nbsp;Massa pada ginjal &lt;3 cm &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sub>τ</sub> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. ..</span></p></li></ul>
<p><span class="font5"><sub>τ</sub>, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- Low grade Iimpoma</span></p>
<p><span class="font5">-KankercervixstdIAl</span></p></td><td style="vertical-align:top;">
<p><span class="font5">Kom</span></p>
<p><span class="font5">Low (&lt;50 y/o)</span></p>
<p><span class="font2">^l</span></p></td><td style="vertical-align:top;">
<p><span class="font5">orbid COVID</span></p>
<p><span class="font0">Medium </span><span class="font5">(50-70 y/o)</span></p>
<p><span class="font2">φl</span></p></td><td style="vertical-align:top;">
<p><span class="font5">19</span></p>
<p><span class="font0">High</span></p>
<p><span class="font5">(&gt;70 y/o)</span></p>
<p><span class="font2">ψi</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font6">Risiko Progresif Penanganan Kanker</span></p></td><td style="vertical-align:bottom;">
<p><span class="font5">Intermediate Zdelav &lt;&nbsp;atau = 3 bulan 1</span></p>
<p><span class="font5">Bedah:</span></p>
<ul style="list-style:none;"><li>
<p><span class="font5">- &nbsp;&nbsp;&nbsp;Kanker prostat dengan risiko tinggi (terapi &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hemato-onkologi:</span></p></li></ul>
<p><span class="font5">androgen dipertimbanhkan) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- Kemoterapi pada kanker payudara </span><span class="font5" style="font-style:italic;">advanced,</span></p>
<ul style="list-style:none;"><li>
<p><span class="font5">- &nbsp;&nbsp;&nbsp;Kanker kolon dengan risiko rendah pada obstruksi &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;kanker kolon dan kanker paru</span></p></li></ul>
<p><span class="font5">iminen &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Onkologi Radiasi:</span></p>
<ul style="list-style:none;"><li>
<p><span class="font5">- &nbsp;&nbsp;&nbsp;Melanoma </span><span class="font5" style="font-style:italic;">Low Risk</span><span class="font5"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;^ Pasca reseksi kanker endometrium</span></p></li>
<li>
<p><span class="font5">- &nbsp;&nbsp;&nbsp;Kanker cervix std 1A2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;^ Risiko tinggi kanker prostat (terapi androgen)</span></p></li></ul></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:middle;">
<p><span class="font1">^l</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:bottom;">
<p><span class="font5">High (Ideal, no delay)</span></p>
<p><span class="font5">Bedah: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hemato-onkologi:</span></p>
<ul style="list-style:none;"><li>
<p><span class="font5">- &nbsp;&nbsp;&nbsp;&gt;2 cm massa pada paru &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;^ Kemoterapi kanker testis, rectum, dan semua -</span></p></li>
<li>
<p><span class="font5">- &nbsp;&nbsp;&nbsp;Kanker kolon dengan obstruksi iminen &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;kanker hematologi </span><span class="font5" style="font-style:italic;">non-low-grade</span></p></li>
<li>
<p><span class="font5">- &nbsp;&nbsp;&nbsp;Kanker endometrium tipe 2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- Sarkoma </span><span class="font5" style="font-style:italic;">non-low-grade</span></p></li>
<li>
<p><span class="font5">- &nbsp;&nbsp;&nbsp;Massa pancreas suspek keganasan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- Kanker bagian leher dan kepala, kecuali tiroid</span></p></li>
<li>
<p><span class="font5">- &nbsp;&nbsp;&nbsp;Massa ovarium suspek keganasan</span></p></li>
<li>
<p><span class="font5">- &nbsp;&nbsp;&nbsp;Massa hepar suspek keganasan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Onkologi Radiasi:</span></p></li>
<li>
<p><span class="font5">- &nbsp;&nbsp;&nbsp;Kanker UroteIial dengan risiki tinggi </span><span class="font5" style="font-style:italic;">non muscle</span><span class="font5"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;^ Kanker paru</span></p></li></ul>
<p><span class="font5" style="font-style:italic;">invasive or muscle invasive</span><span class="font5"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;^ Kanker rectum</span></p>
<ul style="list-style:none;"><li>
<p><span class="font5">- &nbsp;&nbsp;&nbsp;&gt;T 1 b kanker ginjal &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;^ Kanker bagian leher dan kepala</span></p></li>
<li>
<p><span class="font5">- &nbsp;&nbsp;&nbsp;Kanker cervix std IB &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- Kanker ginekologi</span></p></li>
<li>
<p><span class="font5">- &nbsp;&nbsp;&nbsp;Sarkoma </span><span class="font5" style="font-style:italic;">Non -low grade</span><span class="font5"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- Sarkoma </span><span class="font5" style="font-style:italic;">Non-low-grade</span></p></li></ul></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:middle;">
<p><span class="font1">«^</span></p></td></tr>
</table>
<div>
<p><span class="font5">Segera Tindakan Bedah</span></p>
<p><span class="font5">Risiko dengan </span><span class="font5" style="font-style:italic;">Benefit</span><span class="font5"> setara pada Tindakan Bedah</span></p><img src="https://jurnal.harianregional.com/media/58983-3.jpg" alt="" style="width:104pt;height:61pt;">
</div><br clear="all">
<p><span class="font10">Pertimbangan terapi adjuvan bagi penderita tumor solid dengan kemoterapi yang sudah lengkap atau bahkan yang baru memulai kemoterapi, dengan hasil pemeriksaan COVID-19 positif, merupakan langkah terapi pertama yang tepat dengan berbagai pertimbangan secara rasional.<sup>13</sup></span></p>
<p><span class="font10">Selain pertimbangan secara klinis dan hasil pemeriksaan penunjang, terdapat beberapa pertimbangan yang perlu diperhatikan seperti ketersediaan ruang perawatan intensif (RTI), perawatan isolasi yang memadai, ventilator, ketersediaan cadangan darah untuk transfusi, dan tenaga</span></p>
<p><span class="font10">medis yang ahli terutama bidang onkologi di masa COVID-19.</span></p>
<p><span class="font10">Meskipun penderita kanker umumnya dapat dilakukan pembedahan yang bersifat </span><span class="font10" style="font-style:italic;">elective,</span><span class="font10"> namun edukasi kepada penderita dan keluarga merupakan cara yang baik di masa COVID-19 ini. Pemeriksaan yang </span><span class="font10" style="font-style:italic;">standard </span><span class="font10">seperti pemeriksaan darah, </span><span class="font10" style="font-style:italic;">imaging,</span><span class="font10"> dan kontrol lanjutan di poli rawat jalan pun dapat ditunda, dengan tujuan semua ini untuk menurunkan angka penularan COVID-19 terutama kepada ahli bedah onkologi.<sup>3</sup></span></p>
<p><span class="font10">Secara ringkas, perawatan penderita kanker di masa COVID-19 ini, telah mengubah paradigma antara penderita dan tenaga medis terutama ahli bedah onkologi, untuk bersama-sama melawan COVID-19, maka dari itu diperlukan komunikasi yang baik antara dokter dengan penderita, edukasi penyakit dan tindakan prosedur yang dapat ditunda atau segera dikerjakan berdasarkan </span><span class="font10" style="font-style:italic;">guideline</span><span class="font10"> terkini, dan persiapan ketersediaan sumber daya yang ada merupakan pertimbangan yang penting, untuk menekan penyebaran COVID-19 bagi tenaga medis terutama ahli bedah onkologi di Indonesia.</span></p>
<p><span class="font10" style="font-weight:bold;">DAFTAR PUSTAKA</span></p>
<ul style="list-style:none;"><li>
<p><span class="font10">1. &nbsp;&nbsp;&nbsp;Shankar A, Saini D, Roy S, dkk. Cancer care delivery challenges amidst coronavirus disease-19 (COVID-) outbreak: specific precautions for cancer patients and cancer care providers to prevent spread. </span><span class="font10" style="font-style:italic;">Asian Pac J Cancer Prev</span><span class="font10">. 2020;21:569-73.</span></p></li>
<li>
<p><span class="font10">2. &nbsp;&nbsp;&nbsp;Ferguson NM, Laydon D, Nedjati-Gilani G. </span><span class="font10" style="font-style:italic;">Report 9: &nbsp;&nbsp;impact of non</span></p></li></ul>
<p><span class="font10" style="font-style:italic;">pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. Imperial College London</span><span class="font10">. [serial online] 16 Maret 2020 [diakses 01 April 2020]. Diunduh dari: </span><a href="http://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/news--wuhan-coronavirus%20pada%2001%20April%202020"><span class="font10">www.imperial.ac.uk/mrc-global-</span></a></p>
<p><a href="http://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/news--wuhan-coronavirus%20pada%2001%20April%202020"><span class="font10">infectious-disease-analysis/news--wuhan-</span></a><span class="font10"></span><a href="http://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/news--wuhan-coronavirus%20pada%2001%20April%202020"><span class="font10">coronavirus pada 01 April 2020.</span></a></p>
<ul style="list-style:none;"><li>
<p><span class="font10">3. &nbsp;&nbsp;&nbsp;Al-Shamsi H, Alhazzani W, Alhuraiji A, dkk. A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic : An International Collaborative Group. </span><span class="font10" style="font-style:italic;">Oncologist</span><span class="font10">. 2020.</span></p></li>
<li>
<p><span class="font10">4. &nbsp;&nbsp;&nbsp;Lei S, Jiang F, Su W, dkk. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. </span><span class="font10" style="font-style:italic;">EClinicalMedicine</span><span class="font10">. 2020.</span></p></li>
<li>
<p><span class="font10">5. &nbsp;&nbsp;&nbsp;Chen N, Zhou M, Dong X. Epidemiological &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;clinical</span></p></li></ul>
<p><span class="font10">characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a &nbsp;&nbsp;&nbsp;&nbsp;descriptive &nbsp;&nbsp;&nbsp;&nbsp;study. &nbsp;&nbsp;&nbsp;&nbsp;</span><span class="font10" style="font-style:italic;">Lancet</span><span class="font10">.</span></p>
<p><span class="font10">2020;395:507-13.</span></p>
<ul style="list-style:none;"><li>
<p><span class="font10">6. &nbsp;&nbsp;&nbsp;Liang W, Guan W, Chen R. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. </span><span class="font10" style="font-style:italic;">Lancet Oncol</span><span class="font10">. 2020;21:335-37.</span></p></li>
<li>
<p><span class="font10">7. &nbsp;&nbsp;&nbsp;Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. </span><span class="font10" style="font-style:italic;">JAMA Oncol</span><span class="font10">. 2020.</span></p></li>
<li>
<p><span class="font10">8. &nbsp;&nbsp;&nbsp;Kutikov A, Weinberg DS, Edelman MJ, dkk. A war on two fronts: cancer care in the time of COVID-19. </span><span class="font10" style="font-style:italic;">Ann Intern Med</span><span class="font10">. 2020.</span></p></li>
<li>
<p><span class="font10">9. &nbsp;&nbsp;&nbsp;American College of Surgeons. </span><span class="font10" style="font-style:italic;">COVID-19: Elective Case Triage Guidelines for Surgical Care</span><span class="font10">. [serial online] 24 Maret 2020 [diakses 01 April 2020] Diunduh dari:</span><a href="https://www.facs.org/covid-19/clinical-guidance/elective-case"><span class="font10"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;https://www.facs.org/covid-</span></a></p></li></ul>
<p><a href="https://www.facs.org/covid-19/clinical-guidance/elective-case"><span class="font10">19/clinical-guidance/elective-case.</span></a></p>
<ul style="list-style:none;"><li>
<p><span class="font10">10. &nbsp;&nbsp;&nbsp;American Society of Clinical Oncology. </span><span class="font10" style="font-style:italic;">COVID-19 Patient Care Information</span><span class="font10">. [serial online] 02 April 2020 [diakses 02 April &nbsp;&nbsp;&nbsp;&nbsp;2020]. &nbsp;&nbsp;&nbsp;&nbsp;Diunduh &nbsp;&nbsp;&nbsp;&nbsp;dari:</span></p></li></ul>
<p><a href="https://www.asco.org/ascocoronavirus-information/care-individuals-cancer-during-covid-19"><span class="font10">https://www.asco.org/ascocoronavirus-</span></a><span class="font10"></span><a href="https://www.asco.org/ascocoronavirus-information/care-individuals-cancer-during-covid-19"><span class="font10">information/care-individuals-cancer-</span></a><span class="font10"></span><a href="https://www.asco.org/ascocoronavirus-information/care-individuals-cancer-during-covid-19"><span class="font10">during-covid-19.</span></a></p>
<ul style="list-style:none;"><li>
<p><span class="font10">11. &nbsp;&nbsp;&nbsp;Bartlett DL, Howe JR. </span><span class="font10" style="font-style:italic;">Cancer Surgeries in the Time of COVID-19: A Message from the SSO President and PresidentElect</span><span class="font10">. &nbsp;Chicago: Society of Surgical</span></p></li></ul>
<p><span class="font10">Oncology; 2020.</span></p>
<ul style="list-style:none;"><li>
<p><span class="font10">12. &nbsp;&nbsp;&nbsp;American College of Surgeons. </span><span class="font10" style="font-style:italic;">Create a Surgical Review Committee for COVID-19-Related Surgical Triage Decision Making</span><span class="font10">. [serial online] 24 Maret 2020</span></p></li></ul>
<p><span class="font10">[diakses 01 April 2020]. Diunduh dari: </span><a href="https://www.facs.org/covid-19/clinical-guidance/review-committee"><span class="font10">https://www.facs.org/covid-19/clinical-</span></a><span class="font10"></span><a href="https://www.facs.org/covid-19/clinical-guidance/review-committee"><span class="font10">guidance/review-committee.</span></a></p>
<ul style="list-style:none;"><li>
<p><span class="font10">13. &nbsp;&nbsp;&nbsp;Ueda M, Martins R, Hendrie PC, dkk. Managing cancer care during the COVID-19 pandemic: agility and collaboration toward a common goal. </span><span class="font10" style="font-style:italic;">J Natl Compr Canc Netw</span><span class="font10">. 2020;18:1-4.</span></p></li></ul>
<p><span class="font9">S4</span></p>